KR20180020140A - 감마-델타 t 세포 수용체(tcr) 및 키메라 항원 수용체(car)를 발현하는 t 세포 - Google Patents

감마-델타 t 세포 수용체(tcr) 및 키메라 항원 수용체(car)를 발현하는 t 세포 Download PDF

Info

Publication number
KR20180020140A
KR20180020140A KR1020177034648A KR20177034648A KR20180020140A KR 20180020140 A KR20180020140 A KR 20180020140A KR 1020177034648 A KR1020177034648 A KR 1020177034648A KR 20177034648 A KR20177034648 A KR 20177034648A KR 20180020140 A KR20180020140 A KR 20180020140A
Authority
KR
South Korea
Prior art keywords
ser
leu
domain
gly
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177034648A
Other languages
English (en)
Korean (ko)
Inventor
존 앤더슨
조나단 피셔
마틴 푸레
켄스 구스타프슨
Original Assignee
유씨엘 비즈니스 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유씨엘 비즈니스 피엘씨 filed Critical 유씨엘 비즈니스 피엘씨
Publication of KR20180020140A publication Critical patent/KR20180020140A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177034648A 2015-04-30 2016-04-29 감마-델타 t 세포 수용체(tcr) 및 키메라 항원 수용체(car)를 발현하는 t 세포 Ceased KR20180020140A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1507368.7A GB201507368D0 (en) 2015-04-30 2015-04-30 Cell
GB1507368.7 2015-04-30
PCT/GB2016/051235 WO2016174461A1 (en) 2015-04-30 2016-04-29 T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car)

Publications (1)

Publication Number Publication Date
KR20180020140A true KR20180020140A (ko) 2018-02-27

Family

ID=53488907

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177034648A Ceased KR20180020140A (ko) 2015-04-30 2016-04-29 감마-델타 t 세포 수용체(tcr) 및 키메라 항원 수용체(car)를 발현하는 t 세포

Country Status (16)

Country Link
US (2) US20180125890A1 (enExample)
EP (1) EP3288567B1 (enExample)
JP (1) JP6986449B2 (enExample)
KR (1) KR20180020140A (enExample)
CN (1) CN107771215A (enExample)
AU (1) AU2016255611B2 (enExample)
BR (1) BR112017023409A2 (enExample)
CA (1) CA2982532C (enExample)
EA (1) EA201792042A1 (enExample)
ES (1) ES3018558T3 (enExample)
GB (1) GB201507368D0 (enExample)
HK (1) HK1252235A1 (enExample)
IL (1) IL255186B (enExample)
SG (1) SG11201708402UA (enExample)
WO (1) WO2016174461A1 (enExample)
ZA (1) ZA201706923B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
AU2018240556B2 (en) * 2017-03-24 2025-02-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD33 immunotherapy
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
CN111263640A (zh) 2017-09-27 2020-06-09 俄亥俄州创新基金会 组织因子靶向car-nk和car-t细胞疗法
GB201715918D0 (en) * 2017-09-29 2017-11-15 Tc Biopharm Ltd Modified CAR-T
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
GB201804701D0 (en) * 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2019192526A1 (zh) * 2018-04-04 2019-10-10 达仁生物科技有限公司 嵌合抗原受体和其治疗癌症的方法
US12227756B2 (en) * 2018-04-18 2025-02-18 Ucl Business Ltd Engineered regulatory T cell
CN108588023B (zh) 2018-05-09 2020-02-14 河北森朗生物科技有限公司 一种生产嵌合抗原受体修饰的γδT细胞的方法
CN110577932A (zh) * 2018-06-07 2019-12-17 亘喜生物科技(上海)有限公司 一种脐带血来源的嵌合抗原受体t细胞
WO2019242632A1 (en) * 2018-06-19 2019-12-26 1§1Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
CN112368298A (zh) * 2018-06-22 2021-02-12 凯德药业股份有限公司 嵌合跨膜蛋白及其用途
WO2020027094A1 (ja) 2018-07-31 2020-02-06 サイアス株式会社 iPS細胞を介して再生T細胞集団を製造する方法
WO2020033464A1 (en) * 2018-08-07 2020-02-13 H. Lee Moffitt Cancer Center And Research Institute Inc. Car t-cells for the treatment of bone metastatic cancer
US12569507B2 (en) 2018-08-07 2026-03-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T-cells for the treatment of bone metastatic cancer
JP7382603B2 (ja) * 2018-08-10 2023-11-17 国立大学法人京都大学 Cd3陽性細胞の製造方法
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
JP7457007B2 (ja) * 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用CD1d免疫グロブリン
CN109234236A (zh) * 2018-09-29 2019-01-18 吉林大学第医院 一种嵌合抗原受体γδT细胞的制备方法
US12698340B2 (en) * 2018-10-01 2026-08-04 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors
BR112021006182A2 (pt) * 2018-10-01 2021-06-29 Adicet Bio, Inc. composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
WO2020156335A1 (zh) 2019-01-29 2020-08-06 上海交通大学 一种嵌合抗原受体及其应用
US20220088074A1 (en) * 2019-02-21 2022-03-24 Regents Of The University Of Minnesota Genetically modified gamma delta t cells and methods of making and using
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
BR112021017046A2 (pt) * 2019-04-12 2021-11-09 Phanes Therapeutics Inc Receptores de antígeno quiméricos antirreceptores de folato 1 humanizados e seus usos
EP3959307A4 (en) * 2019-04-22 2023-08-23 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
CN113939302A (zh) 2019-06-14 2022-01-14 赛雅思株式会社 医药组合物
US20220259281A1 (en) * 2019-06-21 2022-08-18 Shattuck Labs, Inc. Chimeric protein expressing t-cells
GB201909283D0 (en) * 2019-06-27 2019-08-14 Cancer Research Tech Ltd Fusion proteins with enzyme activity
GB201915359D0 (en) 2019-10-23 2019-12-04 Ucl Business Ltd Engineered regulatory t cell
AU2020370033A1 (en) 2019-10-23 2022-06-02 Ucl Business Ltd Engineered regulatory T cell
CN110981972B (zh) * 2019-12-25 2022-09-30 华夏源(上海)细胞基因工程股份有限公司 一种分泌双特异性抗体的嵌合抗原受体及其表达载体和应用
GB202002581D0 (en) * 2020-02-24 2020-04-08 Gammadelta Therapeutics Ltd Novel antibodies
CR20220431A (es) * 2020-03-03 2023-02-21 Janssen Biotech Inc CÉLULAS T yo Y USOS DE ESTAS
CN117843812A (zh) 2020-05-22 2024-04-09 重庆精准生物技术有限公司 逆转肿瘤微环境的融合蛋白及其应用
CN116348485A (zh) 2020-07-17 2023-06-27 英研生物(英国)有限公司 提供用于过继性细胞疗法的靶向共刺激的受体
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
TW202306997A (zh) 2021-06-16 2023-02-16 英商英斯特生物科技有限公司 用於在過繼細胞療法中提供標靶共刺激之受體
EP4370213A4 (en) 2021-07-16 2025-06-04 Instil Bio (Uk) Limited Chimeric molecules for targeted costimulation for adoptive cell therapy
CN113528455A (zh) * 2021-07-19 2021-10-22 广州百暨基因科技有限公司 表达嵌合抗原受体的γδT细胞
WO2023060126A1 (en) * 2021-10-06 2023-04-13 Dana-Farber Cancer Institute, Inc. Engineered cytokine receptors for tunable adoptive cell therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1147186A4 (en) 1999-01-28 2002-05-15 Palmetto Health Alliance D B A In vitro activated gamma delta lymphocytes
ES2336302T3 (es) 2000-04-03 2010-04-12 Therapure Biopharma Inc. Produccion de celulas ttcr gamma delta.
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
WO2006006720A1 (ja) 2004-07-13 2006-01-19 Medinet., Co.Ltd γδT細胞の培養方法、γδT細胞及び治療・予防剤
ATE476497T1 (de) 2004-08-19 2010-08-15 Univ Cardiff Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
JPWO2008152822A1 (ja) 2007-06-15 2010-08-26 株式会社メディネット 医薬
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9833476B2 (en) * 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US10117896B2 (en) * 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
SG11201507026WA (en) 2013-02-06 2015-10-29 Anthrogenesis Corp Modified t lymphocytes having improved specificity
SG11201505896YA (en) * 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3027204B1 (en) * 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
US9907820B2 (en) 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
EP3858379A1 (en) * 2013-11-21 2021-08-04 Autolus Limited Cell
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
US20170158749A1 (en) * 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
WO2016005752A1 (en) 2014-07-09 2016-01-14 Tc Biopharm Ltd Gamma delta t cells and uses thereof
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
RU2756247C2 (ru) 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CN105158466B (zh) 2015-05-05 2017-12-22 中国科学院广州生物医药与健康研究院 一种检测抗cd19的嵌合抗原受体t细胞对白血病细胞抑制作用的方法

Also Published As

Publication number Publication date
CA2982532C (en) 2023-10-03
ES3018558T3 (es) 2025-05-16
AU2016255611A1 (en) 2017-11-02
EP3288567A1 (en) 2018-03-07
SG11201708402UA (en) 2017-11-29
EA201792042A1 (ru) 2018-03-30
AU2016255611B2 (en) 2021-08-05
CN107771215A (zh) 2018-03-06
BR112017023409A2 (en) 2018-07-24
US20180125890A1 (en) 2018-05-10
IL255186B (en) 2022-02-01
WO2016174461A1 (en) 2016-11-03
IL255186A0 (en) 2017-12-31
JP6986449B2 (ja) 2021-12-22
CA2982532A1 (en) 2016-11-03
US12331316B2 (en) 2025-06-17
EP3288567B1 (en) 2025-03-19
HK1252235A1 (zh) 2019-05-24
US20220211756A1 (en) 2022-07-07
JP2018514204A (ja) 2018-06-07
GB201507368D0 (en) 2015-06-17
ZA201706923B (en) 2022-02-23

Similar Documents

Publication Publication Date Title
AU2016255611B2 (en) T cell which expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR)
KR102957751B1 (ko) Mage a4 t 세포 수용체
CN111819194B (zh) Nyeso t细胞受体(tcr)
RU2717984C2 (ru) Клетка
CN106536563B (zh) 嵌合抗原受体
CN115955977A (zh) 用于过继性细胞疗法的多肽
EP3288970B1 (en) Nucleic acid construct for expressing more than one chimeric antigen receptor
JP2025011176A (ja) 組換え免疫細胞、作製方法、および使用方法
KR102804751B1 (ko) Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포
CN108966652A (zh) 含有三聚体共刺激性tnf家族配体的抗原结合分子
EP3612568A1 (en) Cell
CN114375303B (zh) Magea10特异性t细胞受体及其用途
CN108884167A (zh) 嵌合抗原受体
KR20210021593A (ko) 다양한 구조 최적화를 갖는 t 세포-항원 커플러
CN111479918A (zh) 细胞
CN113840834A (zh) Magea1特异性t细胞受体及其用途
CN119053618A (zh) 嵌合ilt受体组合物和方法
CN112313251B (zh) 结合前列腺特异性膜抗原的嵌合抗原受体
KR20240005865A (ko) Prame 특이적 t 세포 수용체 및 키메라 공동 자극 수용체의 조합
WO2020074868A1 (en) Cell
CN106520806B (zh) 一种重组car基因及其载体、car-t细胞和应用
CN116615446A (zh) Mage-a3特异性t细胞受体及其用途
WO2025140480A1 (zh) 经改造的iNKT细胞
EP4392058A1 (en) Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors
HK40042687A (en) Nyeso t cell receptor (tcr)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210429

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230531

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240522

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230531

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I